New Study Shows Significant Reduction In Opioids, Length Of Hospital Stay And Cost Of Care For Patients Receiving EXPAREL® As The Foundation Of A Multimodal Postsurgical Pain Regimen

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that results from the second IMPROVE study to complete its prospective Phase 4 clinical program were published in the online version of the Journal of Pain Research. The IMPROVE studies assess the differences in postsurgical opioid use and health economic outcomes between patients receiving EXPAREL ® (bupivacaine liposome injectable suspension) as the foundation of an opioid-sparing multimodal regimen versus a standard opioid-based analgesic regimen.

All study patients underwent ileostomy reversal, a surgery performed to reconnect a section of small intestine. Compared to patients in the standard opioid-based treatment arm, patients undergoing the same procedure and receiving an EXPAREL-based multimodal regimen had:
  • A 2.1 day reduction in median length of hospital stay (3.0 days in the EXPAREL group compared to 5.1 days in the IV opioid-based PCA group, respectively; P<0.05)
  • A $2,800 reduction in mean hospitalization costs ($6,482 in the EXPAREL group compared with $9,282 in the IV opioid-based PCA group, respectively; P<0.05)
  • A 92 mg reduction in mean opioid consumption (20 mg in the EXPAREL group compared with 112 mg in the IV opioid-based PCA group, respectively; P<0.05)

“Gastrointestinal motility complications such as intestinal blockages are common following ileostomy reversal, and can be triggered or exacerbated by the use of opioids during and after surgery,” said Jorge E. Marcet, M.D., the study’s lead author and professor and division director of colon and rectal surgery at Morsani College of Medicine, University of South Florida. “In these patients, an opioid-sparing multimodal regimen using EXPAREL was shown to significantly reduce opioid intake, enable earlier discharge and lower the associated costs of care compared to a standard opioid-based pain management strategy.”

The study evaluated 27 adult patients who underwent planned ileostomy reversal procedures at three U.S. sites. Sixteen patients were enrolled in the EXPAREL-based multimodal group; 11 patients were enrolled in the opioid-based group.

If you liked this article you might like

Biotech Premarket Movers: Editas, Amphastar, Aratana, Pacira

Pacira Pharmaceuticals Tops 4Q Earnings Expectations

Biotech Premarket Movers: Pacira, Clearside Biomedical and Organovo

Bullish and Bearish Reversals in the Market

Analysts' Actions -- Quintiles, Royal Caribbean, Western Digital and More